🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  2. BION-1301 Single Dose

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 2 small molecule active

    1 trial

  3. BIS-001ER

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Impaired Awareness Seizures

    phase 2 small molecule active

    1 trial

  4. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  6. BLEOMYCIN

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  7. BLEOPRIM 15 mg polvere per soluzione iniettabile, Carboplatino AHCL 10 mg/ml Concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

  8. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracil 50 mg/ml Solution for Injection or Infusion, LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5 mg/ml Concentrate for Solution for infusion

    Fondazione Telethon ETS

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  9. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracile Teva 250 mg/5 ml soluzione per infusione, CARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione, CETUXIMAB, PEMBROLIZUMAB, Cisplatino Teva Italia 0,5 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

    phase 2 small molecule active

    1 trial

  10. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Prader-Willi Syndrome

    phase 2 small molecule active

    1 trial

  11. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Absence Epilepsy

    phase 2 small molecule active

    1 trial

  12. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IVA

    phase 2 small molecule terminated

    3 trials

  13. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    MPS IV A

    phase 2 small molecule terminated

    2 trials

  14. BMN 165 (rAvPAL-PEG)

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 mab completed

    1 trial

  15. BMN 190

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    2 trials

  16. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial

  17. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  18. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  19. BMN 701

    BioMarin Pharmaceutical Australia Pty Ltd

    Pompe Disease

    phase 2 mab completed

    2 trials

  20. BMS-955176

    ViiV Healthcare B.V.

    HIV Infections

    phase 2 small molecule terminated

    1 trial

  21. BMS-986165

    Bristol-Myers Squibb

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  22. BMS-986165

    Bristol-Myers Squibb

    Lupus Nephritis

    phase 2 small molecule terminated

    1 trial

  23. BMS-986165

    Bristol-Myers Squibb

    Granulomatous Colitis

    phase 2 small molecule terminated

    1 trial

  24. BMS-986470, BMS-986470, N/A, BMS-986470

    Bristol-Myers Squibb Australia Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources